Psomagen’s stock price rose by 3.17% amidst reports of their collaboration with Moderna in genome analysis requests.

this is strong It is interpreted that the collaboration with Modena was highlighted when Moderna, the US, known for its Corona 19 vaccine, announced that it would release an mRNA vaccine for cancer and heart disease by 2030.

As of 10:06 am on the 10th, Psomagen is trading at 7,800 won, up 3.17% from the previous day.

According to foreign media on the 7th (local time), Moderna announced that it would release vaccines to prevent and treat cancer, cardiovascular diseases, and autoimmune diseases by 2030. Experts predict that a groundbreaking new vaccine against various diseases, including cancer, could save millions of lives.

It is analyzed that this is in line with the direction of the cancer conquering project in the United States. On the 3rd (local time), the US Department of Health and Human Services (HHS) unveiled a draft detailed plan for the Biden administration’s cancer conquest project, ‘Cancer Moonshot’. Cancer Moonshot is a policy goal announced by the US government to reduce cancer mortality in Americans by 50% within the next 25 years.

Meanwhile, Psomagen is growing with Moderna. A Psomagen official said, “Quarterly sales to Moderna increased by about 4 times.

He continued, “Moderna has been distributing genome analysis requests here and there on a small scale from the second half of this year to several companies, including Psomagen.” Explained.